SepsisPROBESNCT05024565
Prolonged Intravenous Infusion of β-lactam Antibiotics in Early Septic Patients
A study testing prolonged intravenous infusion of β-lactams Antibiotics in people with Sepsis, run by Qilu Hospital of Shandong University.
Trial summary
The prolonged β-lactam Antibiotics intravenous infusion strategy has emerged as the standard treatment for sepsis despite its unknown efficacy. The investigators will conduct a prospective, multi-center, cluster randomized controlled clinical trial. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Sepsis
- What is being tested?
- prolonged intravenous infusion of β-lactams Antibiotics
- Type of treatment
- Injection or infusion, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,600 participants
- Where
- No sites listed yet
- Study dates
- 20 Sep 2021to 1 Sep 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients in ICU who need to be treated with β-lactam antibiotics for clinical diagnosis of infection;
- Meet the diagnostic criteria of sepsis 3.0 in the previous 24h;
- At assessment of eligibility, treating doctor expects patient to need treatment in ICU beyond the next calendar day.
Who cannot join
- The infection is diagnosed clinically, but the acquired pathogens are not sensitive to the study drug;
- Has a history of allergies to study drugs;
- Those who have a serious condition and the expected survival time is less than 72 hours.
- Receipt of potential study medication for > 24 hours before randomization.
- Pregnancy
- Death is deemed imminent and inevitable.
Show all 9Show fewer
- Receiving palliative or supportive treatment only at the time of assessment for eligibility.
- Treating doctor not committed to provision of advanced life-support, including any of mechanical ventilation, dialysis and vasopressor administration for at least the next 48 hours.
- Consent not gained for study participation and entry under a waiver-of-consent not approved by the jurisdictional human research ethics committee.
About this study
The prolonged β-lactam Antibiotics intravenous infusion strategy has emerged as the standard treatment for sepsis despite its unknown efficacy. The investigators will conduct a prospective, multi-center, cluster randomized controlled clinical trial. The investigators aimed to compare the clinical efficacy and prognosis of prolonged β-lactam antibiotics intravenous infusion versus short-term intravenous infusion in ICU patients with early sepsis. The investigators expect to recruit 40 branch centers and enroll at least 2600 patients with sepsis.
Read the detailed description
Sepsis and septic shock can lead to high morbidity and mortality. The mortality of sepsis is related to inappropriate antibiotic treatment strategy. Due to the pathophysiological characteristics of patients with sepsis, the pharmacokinetics of antibiotics have changed, and antibiotic treatment strategies applied to general mild and severe infections may not be suitable for those patients. The relevant international guidelines recommend that antibiotic treatment for patients with sepsis should base on pharmacokinetic/pharmacodynamic principles, but this recommendation is based on low-level clinical evidence.
β-lactam antibiotics, including penicillins, cephalosporins, carbapenems and so on, are the most widely used antibacterial drugs in clinical practice. The best predictive parameter of those antibiotic bactericidal activity is the time during which the free drug concentration exceeds the target microbial MIC value (fT >MIC). According to Monte Carlo approach and clinical studies, as a PK/PD target value, an effective bactericidal effect can be achieved if fT>MIC reaches more than 40%; fT>MIC reaches more than 60%-70% can achieve the maximum bactericidal effect, which can be used in the treatment of severe cases. For severe infection and prevention of bacterial resistance, fT>MIC needs to reach 90%-100%.
The results of clinical studies have proved that improper or inadequate initial empiric antibiotic treatment is an independent risk factor that affects the therapeutic effectiveness and prognosis of severe infections. Important reasons for the lower-than-expected antibiotic treatment effect in severely ill patients include at least the following two factors: (1) Changes in the pathophysiological state of severely ill patients on drug metabolism, such as capillary leakage leading to increased drug distribution volume. As well as the high excretion and low obstruction hemodynamic characteristics of sepsis, increased renal blood flow leads to high excretion of water-soluble drugs, which often reduces the effective plasma concentration of the drug; (2) ICU infection of pathogenic bacteria has increased drug resistance and increased MIC. The above factors lead to the decrease of drug fT>MIC, which affects the efficacy of antibiotics. In recent years, the optimization of PK/PD-guided time-dependent antimicrobial treatment programs have confirmed that the administration method of prolonging the infusion time or continuous infusion can maintain a good steady-state blood drug concentration, prolong fT> MIC, and improve clinical curative effect, and can reduce the amount of antibiotics.
The main problems with PK/PD-guided antimicrobial therapy are: (1) Lack of convincing large sample clinical research results; (2) It has not been confirmed which subgroup (such as the sepsis severity, drug-resistant patterns of pathogens, immunocompetence) can be benefited from this strategy; (3) It is not clear whether the method of prolonged infusion can be applied in all kinds of β-lactam antibiotics .
This study adopts multi-center, openness, cluster randomization method to group, and eliminates the bias caused by factors such as the treatment environment in a single ward through the multi-center study; through Uniform training realizes the standardization of drug delivery methods to eliminate researchers' human bias in treatment operations and observations. At the same time, the regional randomization method sets the drug delivery method for a certain research center in a certain research phase to be determined, which eliminates the operational error and observation bias when the researcher needs to face multiple drug delivery programs at the same time. It can greatly reduce research costs and human bias, and more reliably obtain the impact of PK/PD-guided antibiotic treatment on the prognosis of patients and the impact of bacterial resistance in the entire ward.
- Conditions
- Sepsis
- Being tested
- prolonged intravenous infusion of β-lactams Antibiotics
- Keywords
- prolonged intravenous infusion, β-lactam Antibiotics, pharmacokinetics/pharmacodynamics (PK/PD)
- Medical subject headings
- Sepsis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
prolonged intravenous infusion of β-lactams AntibioticsBehavioural
(1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
| Study group | Role | What they receive |
|---|---|---|
| prolonged intravenous infusion of β-lactams Antibiotics | Experimental | Administer according to the PK/PD optimized regimen with the goal of increasing T>MIC. (1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours. Receives: Behavioral: prolonged intravenous infusion of β-lactams Antibiotics |
| short-term intravenous infusion of β-lactams Antibiotics | No intervention | The daily allowable dose is calculated according to the creatinine clearance rate. The carbapenems, cephalosporins and β-lactamase inhibitor compound preparations are administered in accordance with the dosage and usage required by the instructions, and the injection is generally 30 minutes. |
What is being measured
The primary outcome is the main question the study is designed to answer.
All-cause mortality in ICU
Prolonged β-lactamase Antibiotics Infusion lower the All-cause mortality in ICU compared with normal group
Measured: Change of mortality between two arms at 90-day from the day antibiotic therapy begin.
28-day all-cause mortality
Prolonged β-lactamase Antibiotics Infusion lower 28-day all-cause mortality the compared with normal group
Measured: Change of mortality between two arms at 28-day from the day antibiotic therapy begin.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2021
- Study start20 Sep 2021 (estimated)
- Primary completion31 Dec 2022 (estimated)
- Study completion1 Sep 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SepsisStudies of the same condition, open and under way.
- More trials run by Qilu Hospital of Shandong UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 2,600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Qilu Hospital of Shandong University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Wang Hao, Qilu Hospital of Shandong University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05024565
- Sponsor's protocol ID
- Wang Hao
- Acronym
- PROBES
- Status last verified
- Aug 2021
- First submitted
- 11 Aug 2021
- Last updated
- 27 Aug 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Study protocol and ICF will be shared with other researchers when start this trial.
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prolonged Intravenous Infusion of β-lactam Antibiotics in Early Septic Patients
- ClinicalTrials.gov ID
- NCT05024565
- Acronym / sponsor ID
- PROBES / Wang Hao
- Conditions
- Sepsis
- Keywords
- prolonged intravenous infusion, β-lactam Antibiotics, pharmacokinetics/pharmacodynamics (PK/PD)
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 2,600 participants (estimated)
- Lead sponsor
- Qilu Hospital of Shandong UniversityUniversity, hospital or other
- Study start
- 20 Sep 2021 (estimated)
- Primary completion
- 31 Dec 2022 (estimated)
- Study completion
- 1 Sep 2023 (estimated)
- First posted
- 27 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The prolonged β-lactam Antibiotics intravenous infusion strategy has emerged as the standard treatment for sepsis despite its unknown efficacy. The investigators will conduct a prospective, multi-center, cluster randomized controlled clinical trial. The investigators aimed to compare the clinical efficacy and prognosis of prolonged β-lactam antibiotics intravenous infusion versus short-term intravenous infusion in ICU patients with early sepsis. The investigators expect to recruit 40 branch centers and enroll at least 2600 patients with sepsis.
Detailed description
Sepsis and septic shock can lead to high morbidity and mortality. The mortality of sepsis is related to inappropriate antibiotic treatment strategy. Due to the pathophysiological characteristics of patients with sepsis, the pharmacokinetics of antibiotics have changed, and antibiotic treatment strategies applied to general mild and severe infections may not be suitable for those patients. The relevant international guidelines recommend that antibiotic treatment for patients with sepsis should base on pharmacokinetic/pharmacodynamic principles, but this recommendation is based on low-level clinical evidence.
β-lactam antibiotics, including penicillins, cephalosporins, carbapenems and so on, are the most widely used antibacterial drugs in clinical practice. The best predictive parameter of those antibiotic bactericidal activity is the time during which the free drug concentration exceeds the target microbial MIC value (fT >MIC). According to Monte Carlo approach and clinical studies, as a PK/PD target value, an effective bactericidal effect can be achieved if fT>MIC reaches more than 40%; fT>MIC reaches more than 60%-70% can achieve the maximum bactericidal effect, which can be used in the treatment of severe cases. For severe infection and prevention of bacterial resistance, fT>MIC needs to reach 90%-100%.
The results of clinical studies have proved that improper or inadequate initial empiric antibiotic treatment is an independent risk factor that affects the therapeutic effectiveness and prognosis of severe infections. Important reasons for the lower-than-expected antibiotic treatment effect in severely ill patients include at least the following two factors: (1) Changes in the pathophysiological state of severely ill patients on drug metabolism, such as capillary leakage leading to increased drug distribution volume. As well as the high excretion and low obstruction hemodynamic characteristics of sepsis, increased renal blood flow leads to high excretion of water-soluble drugs, which often reduces the effective plasma concentration of the drug; (2) ICU infection of pathogenic bacteria has increased drug resistance and increased MIC. The above factors lead to the decrease of drug fT>MIC, which affects the efficacy of antibiotics. In recent years, the optimization of PK/PD-guided time-dependent antimicrobial treatment programs have confirmed that the administration method of prolonging the infusion time or continuous infusion can maintain a good steady-state blood drug concentration, prolong fT> MIC, and improve clinical curative effect, and can reduce the amount of antibiotics.
The main problems with PK/PD-guided antimicrobial therapy are: (1) Lack of convincing large sample clinical research results; (2) It has not been confirmed which subgroup (such as the sepsis severity, drug-resistant patterns of pathogens, immunocompetence) can be benefited from this strategy; (3) It is not clear whether the method of prolonged infusion can be applied in all kinds of β-lactam antibiotics .
This study adopts multi-center, openness, cluster randomization method to group, and eliminates the bias caused by factors such as the treatment environment in a single ward through the multi-center study; through Uniform training realizes the standardization of drug delivery methods to eliminate researchers' human bias in treatment operations and observations. At the same time, the regional randomization method sets the drug delivery method for a certain research center in a certain research phase to be determined, which eliminates the operational error and observation bias when the researcher needs to face multiple drug delivery programs at the same time. It can greatly reduce research costs and human bias, and more reliably obtain the impact of PK/PD-guided antibiotic treatment on the prognosis of patients and the impact of bacterial resistance in the entire ward.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| prolonged intravenous infusion of β-lactams Antibiotics | Experimental | Behavioral: prolonged intravenous infusion of β-lactams AntibioticsAdminister according to the PK/PD optimized regimen with the goal of increasing T>MIC. (1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours. |
| short-term intravenous infusion of β-lactams Antibiotics | No intervention | –The daily allowable dose is calculated according to the creatinine clearance rate. The carbapenems, cephalosporins and β-lactamase inhibitor compound preparations are administered in accordance with the dosage and usage required by the instructions, and the injection is generally 30 minutes. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Patients in ICU who need to be treated with β-lactam antibiotics for clinical diagnosis of infection;
- Meet the diagnostic criteria of sepsis 3.0 in the previous 24h;
- At assessment of eligibility, treating doctor expects patient to need treatment in ICU beyond the next calendar day.
Key exclusion criteria (9 listed)
- The infection is diagnosed clinically, but the acquired pathogens are not sensitive to the study drug;
- Has a history of allergies to study drugs;
- Those who have a serious condition and the expected survival time is less than 72 hours.
- Receipt of potential study medication for > 24 hours before randomization.
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| prolonged intravenous infusion of β-lactams Antibiotics(1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours. | Behavioural | prolonged intravenous infusion of β-lactams Antibiotics |
Primary outcome
All-cause mortality in ICU
Time frame: Change of mortality between two arms at 90-day from the day antibiotic therapy begin.
Prolonged β-lactamase Antibiotics Infusion lower the All-cause mortality in ICU compared with normal group
28-day all-cause mortality
Time frame: Change of mortality between two arms at 28-day from the day antibiotic therapy begin.
Prolonged β-lactamase Antibiotics Infusion lower 28-day all-cause mortality the compared with normal group
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2021.
- Individual participant dataSharing planned: Yes. Study protocol and ICF will be shared with other researchers when start this trial.
Related trials for Sepsis
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Not yet recruiting
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Acute-on-Chronic Liver Failure (ACLF)
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing prolonged intravenous infusion of β-lactams Antibiotics in people with Sepsis, run by Qilu Hospital of Shandong University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
All-cause mortality in ICU (time frame: Change of mortality between two arms at 90-day from the day antibiotic therapy begin.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2021.